

Minutes Nucleus Meeting

1 March 2018, 15:00-18:30, European Heart Agency Offices, Brussels

Present: Basil Lewis, Heinz Drexel, Stefan Agewall, Gianluigi Savarese, Juan Tamargo, Claudio Ceconi, Keld Kjeldsen, Thomas A Schmidt, Giuseppe Rosano, Sven Wassmann

1. Discussion and approval of the minutes from the last nucleus meeting, Vienna, 07 Dec 2017

The minutes were approved without further discussion or comments.

2. WG Development

Basil Lewis

A. Vice-chair election: Alexander Niessner and Giuseppe Rosano are candidates. Giuseppe Rosano gave a presentation of his vision for the Working Group at the end of the meeting.

Alexander Niessner gave a presentation of his vision for the Working Group on 2-MAR-18 at 11:00 (Course coffee break)

B. Plans for election of nucleus members: There are currently 600 members. It is feasible for the Nucleus to nominate new candidates

C. Plans for election of officers in next nucleus: A treasurer and secretary must be nominated.

D. ESC 2018-2020 election update: Each working group has 4 votes for EC elections.

Stephan Acherbach (D), and Bela Merkely (Hun) are running for President. There are several good candidates for Vice President as well

E. Criteria for becoming an association: Not discussed

3. MSc Clinical Trials update:

Basil Lewis, Stefan Agewall, Giuseppe Rosano

The idea is to set up a university course as a triad: ESC body (the Working group), The Heart Academy, a university. A task force has been established. The first meeting of the task force will be in Brussels. The task force needs to select the university with which to collaborate.

Educational Clinical trials courses 2018 (stand-alone):

Tel Aviv in 13 – 14 May (In parallel to the WG Annual Meeting)

Lisbon in 12-13 October.

Prague in 7-8 December

Support from Novo Nordisk and Pfizer established. More may follow.

4. Meetings update

- A. **EuroCVP 2018 May 13-14, 2018.** (Nucleus meeting on 12 May 2018 late afternoon.)
Basil Lewis

Expected Nucleus meeting time: 17:30.

There will be Young Investigator prize and a cases session as well.

ESC, Munich, 2018:
Stefan Agewall, all

Working Group involved in 12 sessions. Good exposure. A Nucleus meeting will also be scheduled.

B. **Other meetings with involvement/endorsement of our WG**

- **Eurothrombosis 2018 Barcelona 4-6 Oct 2018:** Working group involvement not confirmed as yet.
- **Russian Society April 2018 (inflammation, thrombosis):** Gianluigi Savarese and, Juan Carlos Kaski are attending. Invitations have been received. Upon election of Vice Chair Nikita should be contacted in order to facilitate Vice Chair participation in the Russian meeting.
- **International Society of Cardiovascular Pharmacotherapy, May 2018 Japan,** Keld Kjeldsen, Stefan Agewall and Heinz Drexel will be attending.

5. Journal update

Stefan Agewall

120 papers received yearly. Quality increasing. Rejection rate 70%. Position papers and reviews from the Working group are requested. Impact factor evaluation expected this year. 24 papers are published yearly, > 100 citations yearly. Twitter activity established. Altmetric index good. The journal is running with a profit.

6. Update on handbook:

Keld Kjeldsen

Final deadline Monday 5-MAR-18. 9 sections with 5 around chapters each. Must be ready for Munich ESC meeting. 1000 copies will be issued in Japanese. Translation by local ISCP. Royalty Eu 70 for English editions, Eu 0,7 for Japanese ed. Royalty not important whereas visibility, and thus impact is. This also goes for editions in e.g. Russian etc. Translation into European languages not of interest.

7. CV Pharmacotherapists and Trialists of Tomorrow:

Gianluigi Savarese

Progress good

8. Update on webpage:

Alexander Niessner

Not discussed

9. Update on Guidelines, Position Papers and Review Papers

A. Guidelines:

Stefan Agewall

Working group well represented. It would be beneficial with comments to every novel guideline in Journal

B. Position Papers in submission

Giuseppe Rosano, Juan Tamargo

Management of hyperkalaemia in patients receiving RAASI. The paper has been submitted.

C. Position Papers under active development:

Potassium pharmacology – Hypokalemia.

Keld Kjeldsen, Thomas A Schmidt – to be written once the Handbook has been finalized

Inflammation in atherosclerosis: Lipids vs inflammation

Heinz Drexel, Juan Tamargo, Alexander Niessner, Giuseppe Rosano - In progress

D. New proposals

Trilogy of 3 short position papers

1. New definition of endpoints
2. Subgroup analysis
3. Rules for stopping trials

Heinz - In progress. Aim for publication in Journal

Adherence to statins – influence on run-in phase in clinical trials:

Heinz Drexel - Review paper in progress.

Follow-up paper on influence of run-in phase on myopathy

Heinz Drexel

Benefits and safety of the new lipid lowering therapies:

Giuseppe Rosano, support of Juan Tamargo and Heinz Drexel - In progress as a review paper.

Cardiovascular disease in patients with rheumatoid arthritis:

Stefan Agewall, Alexander Niessner and others -There currently is a draft, to be circulated within a month.

Adherence and Cardiovascular Events (multi-pill).

Giuseppe Rosano - In progress

Generics:

Giuseppe Rosano and Juan Tamargo - Important topic. Narrow therapeutic index. Generic drugs may be able to substitute the original drug, but there may important differences, i.e the generic may not work. Aim for position paper

Oral Anticoagulation in Patients with Atrial Fibrillation and a CHA2DS2-VASc Score of 1 Including risk stratification

Patrick Sulzgruber, Alexander Niessner, Christian Torp, Sven Wassmann, including WG on thrombosis– no news

Skip aspirin in triple therapy in collaboration with WG on thrombosis

Patrick Sulzgruber, Alexander Niessner, Sven Wassmann, include WG on thrombosis

Critical Appraisal, COMPASS

Basil Lewis, Alexander Niessner

It was discussed whether the first author of a position paper must or must not necessarily be a Nucleus member. Conclusion pending / left open.

E. Ideas

Pharmacotherapy during CPR

Patrick Sulzgruber, Alexander Niessner -

Specific Effect of Cardiovascular Pharmacotherapy on PAD:

Basil Lewis - Probably a review.

Polypharmacy - Reduce the number of cardiovascular pharmacotherapies:

Thomas A Schmidt, Heinz Drexel, Thomas Walther, Alexander Niessner, Juan Tamargo - pending

Precision medicine based upon phenotype

Thomas A Schmidt, Heinz Drexel, Thomas Walther, Alexander Niessner, Juan Tamargo- pending

Underuse of drugs in cardiovascular disease:

Gianluigi Savarese - pending

Venous diseases: A review of the compounds that are numerous.

Giuseppe Rosano, Juan Tamargo, Heinz Drexel – aiming for a review paper.

Side effects – when and how to act

Keld Kjeldsen, Thomas A Schmidt, Heinz Drexel - in progress

Herbal medicine: Interactions, value

Juan Tamargo, Giuseppe Rosano

10. Finances

Thomas Walther, Stefan Agewall, Basil Lewis

Planned result fiscal year 2018 shows a positive balance is expected. Fewer participants have signed up for the present course. A discussion followed regarding locations with scheduled meetings; or be launched as a university scheduled PhD course. It might also prove advantageous to have a local ambassador for each course. These ideas will be implemented for the next planned courses.

There may be room for additional course subjects. E.g. project management.

11. Other Items

The Angina Awareness Initiative

Giuseppe Rosano – was discussed

ESC council on stroke

Sven Wassmann – Sven reported that very impressive progress had been made in this new ESC council and recommended the continued participation of our WG